Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Construction of m6a-Related lncRNA Signature to Predict Aggressiveness, M6a Modification Level, and Drug Resistance of Hepatocellular Carcinoma

*Corresponding Author:

Copyright: © 2021  . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 
To read the full article Peer-reviewed Article PDF image

Abstract

Backgrounds: Hepatocellular Carcinoma (HCC) is the fourth-ranked malignant tumor with only 18% of 5-year Overall Survival (OS). Currently, the means of invasive detection for HCC patients are still inadequate. M6a methylation has been demonstrated to contribute to tumorigenesis and progression through the regulation of ncRNAs. Therefore, the construction of an asynchronous prediction pattern by m6A-lncRNA regardless of the expressed level is meaningful for HCC patients' diagnosis and potential mechanism study. Methods: We initially identified m6A-lncRNAs through Pearson correlation coefficients. After screening differential m6a-lncRNAs between the cancerous and paracancerous tissues, the lncRNA pairs were formed for further univariate analysis. Incorporate multi-clinical information, we determined 10 pairs of m6A-lncRNA into the prediction model by lasso regression analysis. Next, we determined the optimal cut-off value to distinguish high- and low-risk groups in HCC patients. Finally, we validated the model in terms of survival, clinicopathological characteristics, m6a genes, Tumor Microenvironment (TME), and chemotherapy. Results: Compared with clinical traits such as age, grades, and stages, the model composed of 10 pairs of DEm6A-lncRNA had a better prediction of HCC prognosis in patients. Moreover, it can serve as a risk factor for independent prognosis of HCC patients’ survival status (HR=1.38, p<0.001). Aggressive clinic-pathological characteristics, TME, differences of m6A-regulators, and chemotherapeutics sensitivity were also predictable and separatable according to the pair-model. Conclusion: The research suggests m6a-lncRNA pair-model is critical clinical meaningfulness for clinical prognosis and pathological characteristics, to the TME, and chemotherapeutic effect in HCC.

Keywords

Top